AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) General Information
Description
Rights to the development of a drug for opioid-induced constipation (OIC) treatment. The asset consists of the rights to sell and develop the drug in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein.
Contact Information
Website
www.moventig.comCorporate Office
- 2 Kingdom Street
- London W2 6BD
- England, United Kingdom
Corporate Office
- 2 Kingdom Street
- London W2 6BD
- England, United Kingdom
AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) FAQs
-
Where is AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) headquartered?
AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) is headquartered in London, United Kingdom.
-
What industry is AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) in?
AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein)’s primary industry is Buildings and Property.
-
Is AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) a private or public company?
AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) is a Private company.
-
What is the current valuation of AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein)?
The current valuation of AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) is .
-
What is AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein)’s current revenue?
The current revenue for AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) is .
-
Who are AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein)’s investors?
AstraZeneca has invested in AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein).
-
When was AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) acquired?
AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) was acquired on 01-Mar-2016.
-
Who acquired AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein)?
AstraZeneca (Rights to Moventig in The EU, Iceland, Norway, Switzerland and Liechtenstein) was acquired by Kyowa Kirin International.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process